Author

Pamela Strein

Observed institutions: Heidelberg University, Roche Pharma AG (Germany), University Medical Centre Mannheim

OpenAlex ID: A5050685646

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity

2010 · Ekkehard Mössner, Peter Brünker, et al. · Blood · 1,004

Molecular genetics of Xeroderma pigmentosum variant

2003 · Alexei Gratchev, Pamela Strein, et al. · Experimental Dermatology · 82

PDF

Novel 3rd Generation Humanized Type II CD20 Antibody with Glycoengineered Fc and Modified Elbow Hinge for Enhanced ADCC and Superior Apoptosis Induction.

2006 · Pablo Umana, Ekkehard Moessner, et al. · Blood · 53

GA101, a Novel Humanized Type II CD20 Antibody with Glycoengineered Fc and Enhanced Cell Death Induction, Exhibits Superior Anti-Tumor Efficacy and Superior Tissue B Cell Depletion In Vivo.

2007 · Pablo Umana, Moessner Ekkehard, et al. · Blood · 23

Novel third generation humanized type IICD20 antibody with superior direct cell death induction and glycoengineered Fc region for enhanced ADCC induction

2007 · Pablo Umaña, Ekkehard Moessner, et al. · University of Groningen research database (University of Groningen / Centre for Information Technology) · 2

Works count: 5

Citation count: 1,164

H-index: 4

I10-index: 4